CML-话题@MedSci

#CML#

32篇内容 | 1978人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1488707, encodeId=cdae1488e0758, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？, objectType=article, longId=141184, objectId=8345141184b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8345141184b7, replyNumber=0, likeNumber=64, createdTime=2018-06-22, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8345141184b7, moduleTitle=Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8345141184b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488706, encodeId=95651488e0662, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Cancer：达沙替尼治疗CML：减量/停药时代是否已来临？, objectType=article, longId=136504, objectId=bb85136504ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb85136504ea, replyNumber=0, likeNumber=133, createdTime=2018-04-27, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb85136504ea, moduleTitle=Cancer：达沙替尼治疗CML：减量/停药时代是否已来临？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb85136504ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488705, encodeId=13251488e0594, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=CLIN CHEM：在社区人群中AGE-CML，sRAGE和esRAGE与糖尿病和心脏代谢危险因素的横断面分析, objectType=article, longId=133596, objectId=44cf13359639, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44cf13359639, replyNumber=0, likeNumber=72, createdTime=2018-03-28, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44cf13359639, moduleTitle=CLIN CHEM：在社区人群中AGE-CML，sRAGE和esRAGE与糖尿病和心脏代谢危险因素的横断面分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44cf13359639)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488704, encodeId=76b11488e0425, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Ann Intern Med:CML治疗伊马不行，换尼洛, objectType=article, longId=130873, objectId=0e041308e39a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e041308e39a, replyNumber=0, likeNumber=67, createdTime=2018-03-01, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e041308e39a, moduleTitle=Ann Intern Med:CML治疗伊马不行，换尼洛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e041308e39a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488703, encodeId=05911488e0392, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：hsa-mir183/EGR1-介导的E2F1调控，在CML干/祖细胞存活中发挥重要作用, objectType=article, longId=129564, objectId=0b9412956474, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9412956474, replyNumber=0, likeNumber=75, createdTime=2018-02-12, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9412956474, moduleTitle=Blood：hsa-mir183/EGR1-介导的E2F1调控，在CML干/祖细胞存活中发挥重要作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9412956474)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488702, encodeId=e83e1488e020e, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。, objectType=article, longId=120265, objectId=9356120265b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9356120265b8, replyNumber=0, likeNumber=97, createdTime=2017-11-17, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9356120265b8, moduleTitle=Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9356120265b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488701, encodeId=8a251488e01af, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=JCO：初发CML治疗，伯舒替尼 vs 伊马替尼，孰优孰劣？, objectType=article, longId=119800, objectId=bc70119800aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc70119800aa, replyNumber=0, likeNumber=61, createdTime=2017-11-14, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc70119800aa, moduleTitle=JCO：初发CML治疗，伯舒替尼 vs 伊马替尼，孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc70119800aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488700, encodeId=aa051488e0086, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Ther Drug Monit：标准剂量伊马替尼治疗CML：血药浓度与性别相关？, objectType=article, longId=116357, objectId=a4c411635ec0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4c411635ec0, replyNumber=0, likeNumber=83, createdTime=2017-10-18, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4c411635ec0, moduleTitle=Ther Drug Monit：标准剂量伊马替尼治疗CML：血药浓度与性别相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4c411635ec0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488699, encodeId=d59a148869956, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, objectType=article, longId=105937, objectId=0f0410593e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0410593e49, replyNumber=0, likeNumber=69, createdTime=2017-07-20, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0410593e49, moduleTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0410593e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488698, encodeId=fac91488698de, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=J Clin Oncol：STIM1长期随访研究：CML患者什么情况下可停用伊马替尼？, objectType=article, longId=95711, objectId=461495e1139, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461495e1139, replyNumber=0, likeNumber=74, createdTime=2017-04-15, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461495e1139, moduleTitle=J Clin Oncol：STIM1长期随访研究：CML患者什么情况下可停用伊马替尼？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461495e1139)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488697, encodeId=6149148869e40, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=NEJM：伊马替尼治疗CML的长期疗效, objectType=article, longId=91628, objectId=e4789162853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4789162853, replyNumber=0, likeNumber=97, createdTime=2017-03-15, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4789162853, moduleTitle=NEJM：伊马替尼治疗CML的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4789162853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488696, encodeId=1ac614886964c, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=NEJM: 格列卫（Imatinib）对于慢性粒细胞白血病（CML）十年长期疗效及副作用的报导, objectType=article, longId=91400, objectId=d87e9140061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87e9140061, replyNumber=0, likeNumber=62, createdTime=2017-03-12, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87e9140061, moduleTitle=NEJM: 格列卫（Imatinib）对于慢性粒细胞白血病（CML）十年长期疗效及副作用的报导, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87e9140061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488695, encodeId=9dca14886950e, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, objectType=article, longId=74549, objectId=8dbde45490d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbde45490d, replyNumber=0, likeNumber=41, createdTime=2016-08-07, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbde45490d, moduleTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbde45490d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488694, encodeId=3061148869464, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=伊马替尼治疗CML有何不良反应？, objectType=article, longId=55994, objectId=16c355994c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16c355994c0, replyNumber=0, likeNumber=0, createdTime=2015-09-11, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16c355994c0, moduleTitle=伊马替尼治疗CML有何不良反应？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16c355994c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488693, encodeId=8a0b1488693f4, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=Lancet Haematology：Ponatinib用于治疗慢性期CML，好坏参半, objectType=article, longId=54364, objectId=a462543649b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a462543649b, replyNumber=0, likeNumber=64, createdTime=2015-08-05, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a462543649b, moduleTitle=Lancet Haematology：Ponatinib用于治疗慢性期CML，好坏参半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a462543649b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488692, encodeId=553e1488692a0, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=JMCC：缺血后急性心功能不全可能与MMP2导致的cMLCK降解有关, objectType=article, longId=44698, objectId=afcf446982d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afcf446982d, replyNumber=0, likeNumber=60, createdTime=2014-12-27, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afcf446982d, moduleTitle=JMCC：缺血后急性心功能不全可能与MMP2导致的cMLCK降解有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afcf446982d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488691, encodeId=f426148869114, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, objectType=article, longId=21187, objectId=ad0e2118ed1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad0e2118ed1, replyNumber=0, likeNumber=63, createdTime=2013-07-13, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad0e2118ed1, moduleTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad0e2118ed1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488690, encodeId=dbad148869099, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=关闭CML干细胞活性有望攻克白血病干细胞, objectType=article, longId=13050, objectId=d09e130504b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d09e130504b, replyNumber=0, likeNumber=72, createdTime=2012-12-16, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d09e130504b, moduleTitle=关闭CML干细胞活性有望攻克白血病干细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d09e130504b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488689, encodeId=37f514886892d, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=EHA 2012：达沙替尼治疗CML研究进展, objectType=article, longId=7685, objectId=6a81e685d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a81e685d7, replyNumber=0, likeNumber=78, createdTime=2012-07-08, rootId=0, userName=wangbingxhy, userId=8b3e8470831, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a81e685d7, moduleTitle=EHA 2012：达沙替尼治疗CML研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a81e685d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CML

2020-05-29

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Br J Haematol：CP-CML患者：伊马替尼一线治疗后尼洛替尼怎么样？

2018-06-22

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Cancer：达沙替尼治疗CML：减量/停药时代是否已来临？

2018-04-27

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

CLIN CHEM：在社区人群中AGE-CML，sRAGE和esRAGE与糖尿病和心脏代谢危险因素的横断面分析

2018-03-28

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Ann Intern Med:CML治疗伊马不行，换尼洛

2018-03-01

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Blood：hsa-mir183/EGR1-介导的E2F1调控，在CML干/祖细胞存活中发挥重要作用

2018-02-12

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。

2017-11-17

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

JCO：初发CML治疗，伯舒替尼 vs 伊马替尼，孰优孰劣？

2017-11-14

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Ther Drug Monit：标准剂量伊马替尼治疗CML：血药浓度与性别相关？

2017-10-18

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

J Natl Cancer Inst：CML患者可以停止TKI治疗吗？

2017-07-20

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

J Clin Oncol：STIM1长期随访研究：CML患者什么情况下可停用伊马替尼？

2017-04-15

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

NEJM：伊马替尼治疗CML的长期疗效

2017-03-15

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

NEJM: 格列卫（Imatinib）对于慢性粒细胞白血病（CML）十年长期疗效及副作用的报导

2017-03-12

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加

2016-08-07

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

伊马替尼治疗CML有何不良反应？

2015-09-11

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

Lancet Haematology：Ponatinib用于治疗慢性期CML，好坏参半

2015-08-05

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

JMCC：缺血后急性心功能不全可能与MMP2导致的cMLCK降解有关

2014-12-27

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存

2013-07-13

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

关闭CML干细胞活性有望攻克白血病干细胞

2012-12-16

wangbingxhy (审核中...)

前往app查看评论内容

#CML#

EHA 2012：达沙替尼治疗CML研究进展

2012-07-08

科室
- - 订阅+
  - 更多科室
工具
服务